Human Microbiome Market | Contrive Datum Insights

The Global human microbiome market was valued at USD 712.6 million in 2022 and is expected to reach USD 1,731.1 million by 2030, growing at a CAGR of 19.5% during the forecast period.
{{info}}

The increasing prevalence of chronic diseases, growing awareness about the importance of microbiome in maintaining human health, and rising demand for personalized medicine are some of the key factors driving the growth of the market.

The global human microbiome market refers to the market for products and services related to the study and manipulation of the microorganisms that live in and on the human body. This includes probiotics, prebiotics, microbiome sequencing, and other microbiome-based therapies.

North America is the largest market for human microbiome products and services, followed by Europe and Asia-Pacific. The market is dominated by key players such as DuPont de Nemours, Inc., Seres Therapeutics, Inc., Second Genome Inc., and Enterome Bioscience, among others.

The global human microbiome market is expected to continue to grow in the coming years as researchers and companies continue to explore the potential of the human microbiome in maintaining and improving human health.

Market Dynamics

Driving Factors

There are several driving factors behind the growth of the global human microbiome market:

Rising demand for personalized medicine: As our understanding of the microbiome grows, there is increasing interest in personalized medicine approaches that take into account an individual's unique microbiome composition. This has led to the development of microbiome-based diagnostic tests and therapies.

Technological advancements in microbiome sequencing: The development of new sequencing technologies has made it easier and more cost-effective to study the human microbiome. This has led to an explosion of research in this field and has facilitated the development of new microbiome-based products and services.

Restraining Factors

There are several driving factors behind the growth of the global human microbiome market, there are also some restraining factors that could impact the market growth, including:

High development costs: Developing microbiome-based therapies and diagnostic tests can be expensive and time-consuming. This can make it difficult for smaller companies to enter the market and can limit the number of products that are available.

Competition from existing therapies: There are already a number of established therapies available for the treatment of many chronic diseases. Developing microbiome-based therapies that are more effective than existing treatments can be challenging, particularly given the high cost of development and regulatory challenges.

Challenges

The global human microbiome market faces several challenges that could impact its growth and development, including:

Lack of standardization: There is currently a lack of standardization in terms of sample collection, analysis, and interpretation in the human microbiome field. This can make it difficult to compare results across studies and can hinder the development of reliable microbiome-based products and services.

High development costs: Developing microbiome-based therapies and diagnostic tests can be expensive and time-consuming. This can make it difficult for smaller companies to enter the market and can limit the number of products that are available.

Limited commercialization: Despite the potential of the human microbiome, there are still relatively few microbiome-based products and services available on the market. This can make it difficult to generate revenue and can limit investment in the field.

Ethical considerations: As with any area of medical research, there are ethical considerations related to the use of human subjects and the potential impact of microbiome-based therapies on human health. Addressing these concerns is important to maintain public trust in the field.

Opportunity Factors

The global human microbiome market presents several opportunities for growth and development, including:

Development of new research tools and technologies: The development of new research tools and technologies, such as microbiome sequencing and analysis tools, can help accelerate research in the field and facilitate the development of new products and services.

Expansion into new geographic markets: The global human microbiome market is still relatively nascent, with significant growth potential in emerging markets. This presents an opportunity for companies to expand their operations into new geographic regions and tap into new customer bases.

Segmentation Analysis

Product Outlook

Probiotics are live microorganisms that can provide health benefits when consumed. They are often used to restore and maintain a healthy microbiome.

Prebiotics are non-digestible food components that can promote the growth and activity of beneficial microorganisms in the gut. They are often used in conjunction with probiotics.

Medical foods are specially formulated products that are designed to meet the nutritional needs of patients with specific medical conditions. They can be used to support a healthy microbiome in patients with conditions such as inflammatory bowel disease.

Diagnostic tests can be used to analyze the composition of an individual's microbiome and identify imbalances or dysbiosis that may be contributing to health problems.

Application Outlook

The microbiome has been shown to play a significant role in the development and progression of gastrointestinal disorders, including inflammatory bowel disease, irritable bowel syndrome, and Clostridioides difficile infection. Products targeting these conditions include probiotics, prebiotics, medical foods, and therapeutic drugs.

The microbiome also plays a key role in women's health, particularly in conditions such as bacterial vaginosis and urinary tract infections. Products targeting these conditions include probiotics, prebiotics, and microbiome-based skincare products.

Regional Analysis

The North American market is the largest and most established in the world, with significant investments in microbiome research and development. The US is the largest market in this region, with a large number of companies operating in the space.

{{info2}}

Europe is another significant market for the human microbiome, with a growing number of research studies and a strong regulatory framework. The UK, Germany, and France are the largest markets in this region.

The Asia-Pacific region is expected to grow rapidly in the coming years, driven by increasing investments in microbiome research and the rising prevalence of chronic diseases in the region. Japan, China, and India are the largest markets in this region.

The Rest of the World segment includes regions such as Latin America, the Middle East, and Africa. While these regions are still relatively nascent in the human microbiome market, there is significant growth potential, particularly in emerging markets such as Brazil and South Africa.

North America and Europe currently dominate the global human microbiome market, accounting for the majority of revenue. However, the Asia-Pacific region is expected to grow rapidly in the coming years, driven by increasing investments in microbiome research and the rising prevalence of chronic diseases in the region.

Scope Of Report:

The Global Human Microbiome Market has been segmented into:

By Product Type

• Probiotics
• Prebiotics
• Medical Foods
• Supplements
• Others

By Application

• Therapeutics
• Diagnostics

By Disease

• Obesity
• Diabetes
• Autoimmune Disorder
• Metabolic and Gastrointestinal Disorders
• Cancer
• Other Diseases

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global human microbiome market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• ENTEROME (France)
• Yakult (US)
• DuPont (US)
• Metabiomics Corporation (US)
• ViThera Pharmaceuticals, Inc. (US)
• Second Genome Inc. (US)
• MICROBIOME THERAPEUTICS LLC (US)
• Vedanta Biosciences, Inc. (US)
• Osel, Inc. (US)
• Merck Sharp & Dohme Corp (Germany)
• Seres Therapeutics (US)
• Synthetic Biologics, Inc. (US)
• Synlogic (US), 4D pharma plc (UK)
• Metabogen AB (Sweden)
• Ritter Pharmaceuticals (US)
• Symberix (US)
• Symbiotix Biotherapies, Inc. (US)

Seres Therapeutics: A leading microbiome therapeutics company that develops drugs to treat gastrointestinal and metabolic diseases.

Vedanta Biosciences: A clinical-stage microbiome therapeutics company that develops drugs to treat autoimmune and inflammatory diseases.

Rebiotix: A microbiome therapeutics company that develops drugs to treat Clostridioides difficile infection.

Enterome Bioscience: A microbiome diagnostics and therapeutics company that focuses on gastrointestinal disorders.

Second Genome: A microbiome therapeutics company that develops drugs to treat immune system disorders.

uBiome: A microbiome diagnostics company that offers at-home testing kits for consumers.

BiomX: A microbiome therapeutics company that develops drugs to treat acne and inflammatory bowel disease.

Microbiome Insights: A microbiome testing and analysis company that offers services to academic and industry customers.

BioGaia: A probiotics company that develops and sells products for digestive health and immune support.

Yakult Honsha: A probiotics company that produces and sells fermented milk products containing Lactobacillus casei Shirota.

Strategic Developments

In January 2021, Nestle Health Science announced that it had acquired a majority stake in Vital Proteins, a US-based collagen and dietary supplements company, to expand its presence in the personalized nutrition and wellness space.

In December 2020, Precision for Medicine, a US-based clinical research services company, acquired Epiontis, a German biotech company specializing in epigenetics-based diagnostics and therapeutics.

In November 2020, Finch Therapeutics, a US-based microbiome therapeutics company, announced that it had completed a merger with Crestovo, a special purpose acquisition company (SPAC), to become a publicly traded company.

In August 2020, DuPont Nutrition & Biosciences announced that it had acquired a majority stake in the US-based microbiome startup, DayTwo, to expand its microbiome-based personalized nutrition offerings.

In July 2020, Takeda Pharmaceutical Company announced that it had entered into a research collaboration with the French biotech company Enterome to develop microbiome-based therapeutics for inflammatory bowel disease.

In June 2020, Ferring Pharmaceuticals announced that it had acquired Rebiotix, a US-based microbiome therapeutics company, to expand its presence in the microbiome-based therapies space.

In May 2020, Microbiome Insights, a Canadian microbiome testing and analysis company, announced that it had secured $2.5 million in funding to expand its services and capabilities.